U.S., Sept. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07800871) titled 'FT839 in Autoimmune Diseases' on Aug. 24.
Brief Summary: The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or conditioning therapy.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
ANCA-Associated Vasculitis (AAV)
Idiopathic Inflammatory Myositis (IIM)
Rheumatoid Arthritis (RA)
Systemic Lupus Erythematosus (SLE)
Systemic Sclerosis (SSc)
Intervention:
BIOLOGICAL: FT839
Single Intravenous (IV) infusion of FT839 administered on Day 1 and Da...